Skip to main content
. 2016 Feb 14;7(21):30166–30177. doi: 10.18632/oncotarget.7379

Figure 3. Transcription factors Sp1, ETS1 and AP-2 mediate the SOX9 down-regulation of the CEACAM1 promoter.

Figure 3

Dual luciferase reporter assays were performed with melanoma cells co-transfected with pCEACAM1 wild-type (WT) or mutated pCEACAM1, and with SOX9 overexpression or an empty vector (mock). Luciferase activity was measured and normalized to Renilla activity. Relative luciferase activity was normalized to the luciferase activity of control vector. Experiments were performed in sixplicates. A. Scheme of mutated constructs of the transcription factors' putative binding sites. B. Experiments with mutation of the Sp1 putative binding site C. Experiments with mutations of four ETS1 putative binding sites D. Experiments with deletion of the AP-2 putative binding site. Data in all figures represent the mean ± SEM of at least 3 independent experiments. Asterisks represent P values: *P < 0.05; **P < 0.01; ***P < 0.001 (2-tailed t test).